1BBIO Stock Overview

A commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. More details

1BBIO fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Rewards

Trading at 91.6% below our estimate of its fair value

Earnings are forecast to grow 64.16% per year

Risk Analysis

Has less than 1 year of cash runway

Negative shareholders equity

Shares are highly illiquid

Significant insider selling over the past 3 months

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

BridgeBio Pharma, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for BridgeBio Pharma
Historical stock prices
Current Share Price	US$28.90
52 Week High	US$34.42
52 Week Low	US$32.89
Beta	1.15
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-7.79%

Recent updates

Shareholder Returns

	1BBIO	IT Biotechs	IT Market
7D	-4.4%	3.8%	-0.2%
1Y	n/a	2.7%	16.1%

Return vs Industry: Insufficient data to determine how 1BBIO performed against the Italian Biotechs industry.

Return vs Market: Insufficient data to determine how 1BBIO performed against the Italian Market.

Price Volatility

Is 1BBIO's price volatile compared to industry and market?
1BBIO volatility
1BBIO Average Weekly Movement	n/a
Biotechs Industry Average Movement	8.3%
Market Average Movement	5.5%
10% most volatile stocks in IT Market	8.7%
10% least volatile stocks in IT Market	3.4%

Stable Share Price: 1BBIO's share price has been volatile over the past 3 months compared to the Italian market.

Volatility Over Time: Insufficient data to determine 1BBIO's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2015	728	Neil Kumar	bridgebio.com

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).

BridgeBio Pharma, Inc. Fundamentals Summary

How do BridgeBio Pharma's earnings and revenue compare to its market cap?
1BBIO fundamental statistics
Market cap	€5.53b
Earnings (TTM)	-€591.89m
Revenue (TTM)	€112.90m

49.1x

P/S Ratio

-9.4x

P/E Ratio

Is 1BBIO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1BBIO income statement (TTM)
Revenue	US$127.42m
Cost of Revenue	US$5.92m
Gross Profit	US$121.50m
Other Expenses	US$789.46m
Earnings	-US$667.97m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-3.52
Gross Margin	95.35%
Net Profit Margin	-524.25%
Debt/Equity Ratio	-112.8%

How did 1BBIO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/22 13:18
End of Day Share Price	2025/05/22 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BridgeBio Pharma, Inc. is covered by 25 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
George Farmer	BMO Capital Markets Equity Research
Konstantinos Biliouris	BMO Capital Markets Equity Research
Jason Zemansky	BofA Global Research

BridgeBio Pharma BIT:1BBIO Stock Report